Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Fat in the liver can lead to health complications, including cirrhosis and liver cancer.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.
The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.
Inflammation in people with HIV is associated with cardiovascular disease and other serious health conditions.
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
HIV-positive people with a higher viral load over a longer period appear more likely to develop hepatocellular carcinoma.
This is according to the large randomized controlled START trial.
In an analysis of the liver health of a cohort of HIV/hep B–coinfected people, one third had significant fibrosis.
Those with greater fibrosis before treating hep C see the greatest benefit.
Researchers believe this genetic mutation protected against the 14th century-bubonic plague.
AZT and ddI were the main drugs associated with liver damage in a new study.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.